1Yusuf S, Zhao F, Mehta SR, et al. Effects of elopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345:494-502.
2Mehta SR, Yusuf S, Peters Pal, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PC1-CUBE study. Lancet, 2001,358:527-533.
3Steinhubl SR, Berger PB, Mann .IT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial. JAMA, 2002,288:2411-2420.
4Sabatine MS, Cannon CP, Gibson CM, et al. Addition of Clopidogrel to Aspirin and Fibrinolytie Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med, 2005,352:1179-1189.
5Douglas Jr JS, Holmes Jr DR, Kereiakes D. Cilostazol for restenosis trial: a randomized, double-blind study following coronary artery stent implantation. Late Breaking Clinical Trial Abstracts, AHA,2003. Circulation, 2003, 108:2723. (abstract).
6The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events.Lancet, 1996,348 : 1329-1339.
7Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest,2004,126(3 Suppl) : 5761S-5799S.
8Chairperson SS, Albertsson P, Avil6s FF, et al. Guidelines for percutaneous coronary interventions : The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 2005,26:804 - 847.
9Hennekens CH, Sehror K, Weisman S, et al. Terms and Conditions: Semantic Complexity and Aspirin Resistance.Circulation, 2004,11 : 1706-1708.
10Budaj A, Bfieger D, Steg PG, et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J, 2003,146:999-1006.
